Stay updated on Lebrikizumab Safety & Efficacy in Adolescent AD Clinical Trial

Sign up to get notified when there's something new on the Lebrikizumab Safety & Efficacy in Adolescent AD Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Lebrikizumab Safety & Efficacy in Adolescent AD Clinical Trial page

  1. Check
    7 days ago
    No Change Detected
  2. Check
    14 days ago
    No Change Detected
  3. Check
    21 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    0.9%
    Check dated 2025-02-24T18:34:10.000Z thumbnail image
  4. Check
    28 days ago
    No Change Detected
  5. Check
    36 days ago
    Change Detected
    Summary
    The page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for the Help Desk.
    Difference
    0.9%
    Check dated 2025-02-10T09:24:40.000Z thumbnail image
  6. Check
    43 days ago
    Change Detected
    Summary
    The website has been updated from version v2.14.1 to v2.14.2.
    Difference
    0.1%
    Check dated 2025-02-03T05:17:54.000Z thumbnail image
  7. Check
    50 days ago
    Change Detected
    Summary
    Newly added helpful links related to a study by Eli Lilly on the safety and efficacy of Lebrikizumab for adolescents with moderate-to-severe atopic dermatitis.
    Difference
    0.7%
    Check dated 2025-01-27T02:21:08.000Z thumbnail image
  8. Check
    57 days ago
    Change Detected
    Summary
    The website has been updated from version v2.14.0 to v2.14.1.
    Difference
    0.1%
    Check dated 2025-01-19T19:39:27.000Z thumbnail image
  9. Check
    64 days ago
    Change Detected
    Summary
    The website has updated to version 2.14.0, adding a new type of intervention while removing the previous version's type of intervention and a study link related to Lebrikizumab.
    Difference
    0.9%
    Check dated 2025-01-12T16:51:10.000Z thumbnail image

Stay in the know with updates to Lebrikizumab Safety & Efficacy in Adolescent AD Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Lebrikizumab Safety & Efficacy in Adolescent AD Clinical Trial page.